REG - BkofA Merrill Lynch Horizon Therapeutics - 20230405_HORIZON THERAPEUTICS PLC_38.5 (b)_BOFAS

AmgenAnnouncement

06/04/2023 11:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230406:nRSF6422Va&default-theme=true

RNS Number : 6422V  Bank of America Merrill Lynch  06 April 2023

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT

RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY

STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

 1.  KEY INFORMATION

 Name of exempt principal trader             BofA Securities, Inc.
 Company dealt in                            HORIZON THERAPEUTICS PLC
 Class of relevant security to which the     Common - IE00BQPVQZ61

dealings being disclosed relate(Note 1)
 Date of dealing                             05/04/2023

BofA Securities, Inc.

 Company dealt in

HORIZON THERAPEUTICS PLC

 Class of relevant security to which the

dealings being disclosed relate(Note 1)

Common - IE00BQPVQZ61

 Date of dealing

05/04/2023

 

 2.  INTERESTS AND SHORT POSITIONS

 (a)  Interests and short positions (following dealing) in the class of relevant
      security

dealt in (Note 2)

 Class of relevant security: Common             IE00BQPVQZ61
                                                Long             Short
                                                Number   %       Number   %
 (1)  Relevant securities                       415,953  0.182%  96,511   0.042 %
 (2)  Derivatives (other than options):         581,381  0.254%  568,294  0.248%
 (3)  Options and agreements to purchase/sell:  0        0%      68,300   0.030%
 Total                                          997,334  0.436%  733,105  0.320%

415,953

0.182%

96,511

0.042 %

 (2)  Derivatives (other than options):

581,381

0.254%

568,294

0.248%

 (3)  Options and agreements to purchase/sell:

0

0%

68,300

0.030%

Total

997,334

0.436%

733,105

0.320%

 

 (b)  Interests and short positions in relevant securities of the company, other
      than the

class dealt in (Note 2)

 Class of relevant security:
                                                Long         Short
                                                Number  %    Number  %
 (1)  Relevant securities                       0       0%   0       0%
 (2)  Derivatives (other than options):         0       0%   0       0%
 (3)  Options and agreements to purchase/sell:  0       0%   0       0%
 Total                                          0       0%   0       0%

0

0%

0

0%

 (2)  Derivatives (other than options):

0

0%

0

0%

 (3)  Options and agreements to purchase/sell:

0

0%

0

0%

Total

0

0%

0

0%

 3.  DEALINGS (Note 3)

 (a)  Purchases and sales

 Purchase/sale  Number of relevant securities  Price per unit (Note 4)
 Purchase       300                            107.99 USD
 Purchase       2,500                          107.98 USD
 Purchase       8,700                          108 USD
 Purchase       3,657                          107.9 USD
 Purchase       1,200                          107.995 USD
 Purchase       1,000                          107.998 USD
 Purchase       1,300                          107.895 USD
 Purchase       405                            107.75 USD

 

 Purchase/sale  Number of relevant securities  Price per unit (Note 4)
 Sale           621                            108.9 USD
 Sale           500                            108.86 USD
 Sale           200                            108.88 USD
 Sale           100                            108.87 USD
 Sale           537                            108.79 USD
 Sale           1,263                          108.78 USD
 Sale           200                            108.785 USD
 Sale           100                            108.84 USD
 Sale           256                            108.82 USD
 Sale           100                            108.845 USD
 Sale           100                            108.77 USD
 Sale           223                            108.865 USD
 Sale           200                            108.805 USD
 Sale           20                             108.43 USD
 Sale           99                             108.44 USD
 Sale           42                             108.48 USD
 Sale           100                            108.605 USD
 Sale           200                            108.54 USD
 Sale           100                            108.63 USD
 Sale           194                            108.68 USD
 Sale           406                            108.64 USD
 Sale           300                            108.67 USD
 Sale           400                            108.655 USD
 Sale           200                            108.775 USD
 Sale           200                            108.855 USD
 Sale           700                            108.675 USD
 Sale           100                            108.788 USD
 Sale           100                            108.778 USD
 Sale           2,500                          108.1 USD
 Sale           100                            108.688 USD
 Sale           100                            108.678 USD
 Sale           100                            108.683 USD

 

 

 (b)  Derivatives transactions (other than options transactions)

 Product name,  Nature of transaction  Number of relevant securities  Price per unit

e.g. CFD
(Note 5)              (Note 6)
(Note 4)
 N/A            N/A                    N/A                            N/A

 

 (c)  Options transactions in respect of existing relevant securities

 (i)  Writing, selling, purchasing or varying

 Product name, e.g. call option  Writing, selling, purchasing, varying etc.  Number of securities to which the option relates (Note 7)  Exercise price  Type, e.g. American, European etc  Expiry date  Option money paid/ received per unit (Note 4)
 N/A                             N/A                                         N/A                                                        N/A             N/A                                N/A          N/A

 

 (ii)  Exercising

 Product name,      Number of securities  Exercise price per

e.g. call option
unit (Note 4)
 N/A                N/A                   N/A

 

 (d)  Other dealings (including transactions in respect of new securities) (Note 3)

 Nature or transaction  Details  Price per unit
 (Note 7)
(if applicable) (Note 4)
 N/A                    N/A      N/A

 

 4.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 Full details of any agreement, arrangement or understanding between the person

disclosing and any other person relating to the voting rights of any relevant

securities under any option referred to on this form or relating to the voting
 rights

or future acquisition or disposal of any relevant securities to which any
 derivative

referred to on this form is referenced. If none, this should be stated.
 None

 

 Is a Supplemental Form 38.5(b) attached? (Note 8)  No

 

 Date of disclosure                            06/04/2023
 Contact name                                  Frank Lui
 Telephone number                              +44207 996 6418
 Name of offeree/offeror with which connected  AMGEN INC
 Nature of connection (Note 9)                 Advisor to - AMGEN INC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISEUPUQPCUPWUBQ